Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Research & Development: 2014-2024

Historic Research & Development for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to $697.9 million.

  • Ultragenyx Pharmaceutical's Research & Development rose 27.10% to $216.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $734.5 million, marking a year-over-year increase of 9.52%. This contributed to the annual value of $697.9 million for FY2024, which is 7.62% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Research & Development stood at $697.9 million for FY2024, which was up 7.62% from $648.4 million recorded in FY2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Research & Development peaked at $705.8 million during FY2022, and registered a low of $412.1 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $697.9 million (2024), whereas its average is $684.0 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Research & Development skyrocketed by 41.97% in 2022 and then declined by 8.12% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Research & Development (Yearly) stood at $412.1 million in 2020, then rose by 20.64% to $497.2 million in 2021, then spiked by 41.97% to $705.8 million in 2022, then decreased by 8.12% to $648.4 million in 2023, then rose by 7.62% to $697.9 million in 2024.